PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
37.65
+0.27 (+0.72%)
At close: 4:02PM EDT

37.76 +0.09 (0.24%)
Pre-Market: 7:00AM EDT

Stock chart is not supported by your current browser
Previous Close37.38
Open37.46
Bid37.52 x 800
Ask37.69 x 900
Day's Range37.45 - 37.77
52 Week Range32.32 - 39.43
Volume14,933,586
Avg. Volume20,408,223
Market Cap220.236B
Beta0.92
PE Ratio (TTM)10.46
EPS (TTM)3.60
Earnings DateJul 31, 2018
Forward Dividend & Yield1.36 (3.66%)
Ex-Dividend Date2018-08-02
1y Target Est39.80
Trade prices are not sourced from all markets
  • Reuters4 minutes ago

    Hikma raising injectable opioids output to help ease shortage at U.S. hospitals

    London-listed pharmaceutical group Hikma said on Wednesday it was increasing its supply of hydromorphone to U.S. hospitals to help ease a shortage of injectable opioids used to treat patients. Injectable opioid painkillers, which hospitals use to manage pain after operations and in terminal illness, have been in short supply for more than a year largely due to production problems at Pfizer, the biggest supplier of the drugs. Pfizer has said it is making progress on its recovery plan, but it estimates that the supply of some of its injectables will not be fully restored until later this year or in 2019.

  • Reuters7 minutes ago

    Pfizer-Lilly pain drug found effective in late-stage study

    An experimental drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of reducing pain in osteoarthritis patients in a late stage trial, the companies said on Wednesday. The study showed ...

  • Reuters11 minutes ago

    Novartis joins Pfizer in halting U.S. drug price hikes

    Novartis expects to hit the top of its 2018 sales guidance after a strong second quarter, the CEO said, despite joining Pfizer in freezing its U.S. drug prices for the rest of the year following pressure from President Donald Trump. Chief Executive Vas Narasimhan said Novartis would likely easily achieve mid-single digit percentage sales growth for 2018, on rising demand for psoriasis-and-arthritis drug Cosentyx and robust sales of heart-failure medicine Entresto. "We would expect to see, assuming continued momentum like we're seeing now, to be at the high end of that range," Narasimhan said, adding that this would come without price hikes as Novartis keeps the lid on medicine costs under pressure from U.S. lawmakers and Trump.

  • Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain
    Business Wire20 minutes ago

    Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain

    Pfizer Inc.(PFE) and Eli Lilly and Company (LLY) today announced that a 16-week Phase 3 study in patients with osteoarthritis (OA) pain evaluating subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, met all three co-primary endpoints. The study demonstrated that patients who received two doses of tanezumab separated by eight weeks experienced a statistically significant improvement in pain, physical function and the patients’ overall assessment of their OA, compared to those receiving placebo. Tanezumab is part of an investigational class of pain medications known as nerve growth factor (NGF) inhibitors and in addition to OA pain, is being evaluated for chronic low back pain (CLBP) and cancer pain (due to bone metastases).

  • Novartis joins Pfizer in halting U.S. drug price hikes
    Reuters45 minutes ago

    Novartis joins Pfizer in halting U.S. drug price hikes

    Novartis (NOVN.S) expects to hit the top of its 2018 sales guidance after a strong second quarter, the CEO said, despite joining Pfizer (PFE.N) in freezing its U.S. drug prices for the rest of the year following pressure from President Donald Trump. Chief Executive Vas Narasimhan said Novartis would likely easily achieve mid-single digit percentage sales growth for 2018, on rising demand for psoriasis-and-arthritis drug Cosentyx and robust sales of heart-failure medicine Entresto. "We would expect to see, assuming continued momentum like we're seeing now, to be at the high end of that range," Narasimhan said, adding that this would come without price hikes as Novartis keeps the lid on medicine costs under pressure from U.S. lawmakers and Trump.

  • Novartis Joins Pfizer in Holding Line on Drug Prices in U.S.
    Bloomberg4 hours ago

    Novartis Joins Pfizer in Holding Line on Drug Prices in U.S.

    Swiss drugmaker Novartis AG is holding the line on U.S. prices this year as an attack from President Donald Trump led rival Pfizer Inc. to delay planned increases for some medicines. Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday. Pfizer last week agreed to defer planned price increases for certain drugs a day after Trump criticized the company over reported plans to raise them.

  • Novartis CEO Says Drugmaker Won't Raise U.S. Prices This Year
    Bloomberg4 hours ago

    Novartis CEO Says Drugmaker Won't Raise U.S. Prices This Year

    Swiss drugmaker Novartis AG is holding the line on prices in the U.S. this year, following a move by rival Pfizer Inc. to delay planned increases for some medicines after President Donald Trump launched an attack on the U.S. pharma giant. Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday with journalists. Pfizer last week agreed to defer planned price increases for certain drugs a day after Trump targeted Pfizer over reported plans to implement a series of price increases, criticizing the move on Twitter and briefly rattling its shares.

  • Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III
    Zacks16 hours ago

    Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III

    Pfizer (PFE) initiates phase III program on a gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B.

  • Investopedia20 hours ago

    TD Ameritrade: Setting Time Target Best Way for Investors to Ignore Noise

    Geopolitical tensions are rising, and trade disagreements are increasing, leaving investors confused as to how to react to the daily headlines emanating out of Washington and Wall Street. A better option, one advocated by TD Ameritrade's chief market strategist J.J. Kinahan, is to set a time target on the investments in a portfolio and stick to it. "A lot of people set price targets, but they don't do a good enough job setting a time target," said Kinahan in an interview with Investopedia.

  • CNBC21 hours ago

    Johnson & Johnson CEO defends drug prices, calls for changes in how medical costs are covered

    Johnson & Johnson CEO Alex Gorsky called for changes in the way prescription drugs are paid for but stopped short of saying pharmaceutical companies need to lower the prices they charge.

  • Investopedia21 hours ago

    How Johnson & Johnson Became A Household Name

    New Brunswick, N.J.-based Johnson & Johnson (NYSE:  JNJ) is probably most famous as the parent company of multiple household products that double as household names. If you’ve ever bandaged a wound, rinsed your mouth, applied lotion, sanitized your hands, battled a headache, substituted sugar or treated heartburn, chances are excellent that you did so courtesy of Johnson & Johnson’s research and development. To quote company Chairman and CEO Alex Gorsky, “approximately 70% of our sales come from products with the number one or number two global market share position.” Johnson & Johnson boasts no fewer than 275 subsidiary companies, up from 250 three years ago.

  • CNBCyesterday

    Increasing drug prices despite public scrutiny 'makes absolutely no sense,' says analyst

    Some drug companies continue to raise prices, despite mounting public scrutiny and pressure from the president. Pfizer raised the price of more than 40 medications at the beginning of July. "The pharmaceutical industry is very much addicted to price inflation in terms of growth," said analyst Elliot Wilbur.

  • Pfizer begins late-stage testing of Spark's hemophilia B gene therapy
    American City Business Journals2 days ago

    Pfizer begins late-stage testing of Spark's hemophilia B gene therapy

    The two companies, which said a licensing deal in 2014, have completed the transfer of the therapy's development from Spark to Pfizer.

  • UAB researchers make big discovery on diabetes research
    American City Business Journals2 days ago

    UAB researchers make big discovery on diabetes research

    UAB researchers have made a significant discovery in diabetes research – one that could reduce the skyrocketing costs of treatment.

  • Investopedia2 days ago

    Analysis: Motivating Factors Behind Pfizer’s Big Split

    Pfizer, the worlds second largest pharmaceutical company, announced on Wednesday, July 11th, plans to split into three separate businesses in a major restructuring move. The Innovative Medicines division will bring in most of Pfizer’s revenue. In a press release, the company said that the growth potential for that business is strongest in part because of the aging population which will increase the demand for new medicines.

  • Business Wire2 days ago

    Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy

    Pfizer Inc. (PFE) and Spark Therapeutics (ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in the usual care setting. The factor IX prophylaxis efficacy data obtained in the lead-in study will serve as the within-subject control group for those patients that enroll into the next part of the Phase 3 study, which will evaluate the investigational gene therapy fidanacogene elaparvovec for the treatment of hemophilia B. The interventional portion of this pivotal Phase 3 study will enroll patients who have completed at least six months in the lead-in study.

  • Pfizer's Reorganizing Again. Is Its Stock a Buy Now?
    Motley Fool2 days ago

    Pfizer's Reorganizing Again. Is Its Stock a Buy Now?

    The drugmaker's second reorganization in four years signals where the company is headed. But it doesn't solve its most serious problem.

  • Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population
    Zacks2 days ago

    Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population

    FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.

  • With General Electric Gone, Which Dow Component Will Be Kicked Out Next?
    Motley Fool2 days ago

    With General Electric Gone, Which Dow Component Will Be Kicked Out Next?

    Three Dow stocks could be on the hot seat, but one looks like a sure shot to be shown the door next year.

  • The Wall Street Journal2 days ago

    [$$] This Form of Ambien Now Costs Over 800% More

    A small Colorado drugmaker recently raised the price for a spray form of sleep aid Ambien by as much as 843%, the latest example of how some firms are increasing prices despite mounting pressure. The median price increase is 8%, but some specific increases have been far greater. Aytu BioScience Inc. raised the list price of a 7.7 milliliter bottle of its sleep aid Zolpimist to $659 from $69.88, while increasing the price of a 4.5 milliliter bottle by 747% to $329.50, according to RELX PLC’s Elsevier Gold Standard Drug Database.

  • Novartis Looks to Exit Antibacterial, Antiviral Program
    Zacks5 days ago

    Novartis Looks to Exit Antibacterial, Antiviral Program

    Per media sources, Novartis is looking to exit its antibacterial and antiviral research program, and cut its headcount.

  • U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
    Business Wire5 days ago

    U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

    Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide), following FDA Priority Review designation, based on results from the Phase 3 PROSPER trial. The FDA action broadens the indication for XTANDI to men with castration-resistant prostate cancer (CRPC), now including men with non-metastatic CRPC. This approval makes XTANDI the first and only oral medication FDA-approved for both non-metastatic and metastatic CRPC.

  • PR Newswire5 days ago

    U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

    First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC TOKYO and NEW YORK , July 13, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa ...

  • 7 Hot Stocks Savvy Investors Are Buying
    InvestorPlace5 days ago

    7 Hot Stocks Savvy Investors Are Buying

    Did you ever copy from the smart kid in class and then score straight A’s? Well, now you can replicate this savvy move with top investor trades — and make some money while you’re at it!

  • Drugmakers will think twice on price increases after Trum...
    CNBC Videos2 days ago

    Drugmakers will think twice on price increases after Trum...

    Elliot Wilbur, Raymond James specialty pharmaceuticals analyst, discusses the rising cost of prescription drugs and how President Trump is tackling the issue.